Relay Therapeutics, Inc.

NASDAQ:RLAY

Biotechnology

Healthcare
$16.51 +2.63%

+$0.41 today

Market cap
$3.65B
Beta
1.75
P/E (TTM)
-10.5
EPS (TTM)
-$1.52
52W Low $3.03High $17.47

Volume 2.43M

Average 3.70M

RLAY Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Relay Therapeutics, Inc.NASDAQ: RLAY

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) growth accelerates

Q2 FY2026 weighted avg shares (diluted) of 202.85M shares rose 18.4% year over year, ahead of the +12.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 12.8% from the prior quarter. Over 3 fiscal years it compounded at +15.2% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +18.4% holds above the trailing-twelve-month pace of +12.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
202.85M+12.8% QoQ
Last fiscal yearDec 2025
171.59M+20.1% YoY
LTMJun 2026
181.67M+12.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.4%——
1 year+20.1%——
3-year CAGR+15.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
171.59M USD
Year-over-year change
+20.1%
4-year CAGR
+15.9%

Weighted Avg Shares (Diluted) vs competitors

How RLAY compares with its peers on the latest reported figures

  • RLAY's LTM Jun 2026 weighted avg shares (diluted) of 181.67M shares is the 3rd highest of the 11 companies compared; the peer median is 92.22M shares.
  • Its year-over-year change of +12.1% is the 6th highest of 11, against a peer median of +13.5%.
  • Over three fiscal years its annual growth of +15.2% compares with a peer median of +19.4%.
RLAY Competitors Peer median
Weighted Avg Shares (Diluted) for RLAY and competitors
Company Period LTM YoY 3-year CAGR
ERASErasca, Inc.LTM Sep 2026310.86M +9.7%+32.5%
RVMDRevolution Medicines, Inc.LTM Jun 2026197.09M +10.9%+33.1%
RLAYRelay Therapeutics, Inc.LTM Jun 2026181.67M +12.1%+15.2%
TNGXTango Therapeutics, Inc.LTM Sep 2026145.89M +32.5%+9.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026108.1M +31.0%+21.3%
ORICORIC Pharmaceuticals, Inc.LTM Mar 202692.59M +31.1%+30.3%
KYMRKymera Therapeutics, Inc.LTM Jun 202691.85M +16.0%+16.1%
IDYAIDEAYA Biosciences, Inc.LTM Mar 202688.86M +4.6%+28.8%
PRLDPrelude Therapeutics IncorporatedLTM Mar 202674.4M -1.9%+17.6%
TYRATyra Biosciences, Inc.LTM Mar 202660.14M +2.0%+12.5%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 202640.11M +19.2%+4.7%
Peer median (excluding RLAY) 92.22M+13.5%+19.4%

Competitors are the stored peer set for RLAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.03M1.38M25.55M10.01M15.36M
Cost of Revenue169.39M243.01M326.39M315.44M3.56M
Gross Profit(166.36M)(241.62M)(300.84M)(305.43M)11.8M
Gross Margin-5492.2%-17496.3%-1177.6%-3052.2%76.8%
Research & Development295.65M246.36M330.02M319.09M261.38M
Selling, General & Admin59.75M69.33M78.58M80.24M56.71M
Operating Expenses198.34M57.65M72.16M67.03M314.54M
Depreciation & Amortization3.93M4.13M5.27M5.46M3.56M
EBITDA(223.08M)(306.82M)(374.15M)(380.21M)(272.92M)
EBITDA Margin-7364.9%-22217.4%-1464.6%-3799.4%-1777.4%
Operating Income(364.7M)(299.28M)(373M)(372.47M)(302.74M)
Operating Margin-12040.2%-21670.9%-1460.1%-3722.1%-1971.6%
Interest Income830K8.79M31.05M34.75M27.04M
Interest Expense00000
Other Income / Expenses826K8.77M31.03M34.76M26.26M
Income Before Tax(363.87M)(290.51M)(341.97M)(337.71M)(276.48M)
Pre-Tax Margin-12012.9%-21036.1%-1338.7%-3374.7%-1800.6%
Income Tax Expense00000
Net Income(363.87M)(290.51M)(341.97M)(337.71M)(276.48M)
Net Margin-12012.9%-21036.1%-1338.7%-3374.7%-1800.6%
EPS (Basic)(3.82)(2.59)(2.79)(2.36)(1.61)
EPS (Diluted)(3.82)(2.59)(2.79)(2.36)(1.61)
Weighted Avg Shares95.14M112.23M122.58M142.87M171.59M
Weighted Avg Shares (Diluted)95.14M112.23M122.58M142.87M171.59M

Relay Therapeutics, Inc.

NASDAQ:RLAY

Intrinsic Alpha fair value

Locked

Current Price

$16.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.